Exhibition Open
11:00 - 18:00
Exhibition
Industry Session
11:15 - 12:00
Industry Mini Session
Programme will be available when approved by the company
IMS02 The importance of treating anhedonia as part of effective major depressive disorder (MDD)
management
11:15 - 12:00
Industry Mini Session
Industry session financially supported by H. Lundbeck A/S
Anhedonia, the inability or reduced ability to experience pleasure, is experienced by ~75% of adults with
major depressive disorder (MDD) [1]. Associated with disturbances of reward circuit pathways, anhedonia
may lead to impaired motivation, pleasure and reward processing [2], negatively affecting functioning and
overall quality of life [3,4]. Anhedonic features may act as independent predictors of poor treatment
response in patients with MDD [5].
This symposium will explore the impact of anhedonia on patients with MDD and discuss approaches to
treating anhedonia as part of comprehensive care. Philip Gorwood will provide an overview of anhedonia
as a core symptom of MDD, discussing how it is typically defined and exploring the aetiology. Patient and
clinician perspectives on the prevalence and severity of anhedonia will be reviewed, and the burden of
anhedonia on patients with MDD will be discussed, with a focus on quality of life, social functioning,
physical health and suicide risk. The impact of anhedonia on treatment response and outcomes will be
presented.
Marco Di Nicola will then explore the impact of antidepressant treatments on anhedonia, presenting data
that show the effectiveness of some antidepressants on anhedonia across patients with MDD, including
data on subpopulations with different characteristics and treatment needs. The session will conclude with
a question-and-answer panel discussion, during which your active participation is encouraged.
References
[1] Franken, I.H.A., Rassin, E., Muris, P., 2007. The assessment of anhedonia in clinical and non-clinical
populations: further validation of the Snaith-Hamilton Pleasure Scale (SHAPS). J Affect Disord 99(13),
8389.
[2] Su, Y.-A., Si, T., 2022. Progress and challenges in research of the mechanisms of anhedonia in major
depressive disorder. Gen Psychiatr 35(1), e100724.
[3] Cronquist Christensen, M., Ren, H., Fagiolini, A., 2022. Emotional blunting in patients with depression.
Part II: relationship with functioning, well-being, and quality of life. Ann Gen Psychiatry 21(1), 20.
[4] Buckner, J.D., Joiner Jr., T.E., Pettit, J.W., Lewinsohn, P.M., Schmidt, N.B., 2008. Implications of the
DSMs emphasis on sadness and anhedonia in major depressive disorder. Psychiatry Res 159(12 ):25
30.
[5] Luca, A., Luca, M., Kasper, S., Pecorino, B., Zohar, J., Souery, D., Montgomery, S., Ferentinos, P., Rujescu,
D., Messina, A., Zanardi, R., Ferri, R., Tripodi, M., Baune, B.T., Fanelli, G., Fabbri, C., Mendlewicz, J., Serretti,
A., 2024. Anhedonia is associated with a specific depression profile and poor antidepressant response. Int
J Neuropsychopharmacol 27(12), pyae055.
Industry Session
11:15 - 12:00
Industry Mini Session
Programme will be available when approved by the company
Industry Session
11:15 - 12:00
Industry Mini Session
Programme will be available when approved by the company
Lunch
12:00 - 13:25
Break
Poster session
12:00 - 13:25
Poster Session
Industry Session
13:20 - 14:40
Industry Satellite Symposium
Programme will be available when approved by the company
ISS02 Personalising pharmacotherapy for people with schizophrenia: leveraging patient preferences
and pharmacokinetics data
13:20 - 14:40
Industry Satellite Symposium
Industry session financially supported by Otsuka Pharmaceutical Europe Ltd & [Link] A/S
This meeting has been organised and funded by Otsuka Pharmaceutical Europe Ltd and H. Lundbeck A/S.
Information on Otsuka Pharmaceutical Europe Ltd and H. Lundbeck A/S products will be presented at this
meeting, which is intended for healthcare professionals only.
Real-world studies have indicated that treatment formulations with dosing intervals longer than one
month may offer several advantages for people diagnosed with schizophrenia, including greater
convenience and a reduction in both treatment and caregiver burden.[1,2] When recommending an
antipsychotic, prescribers should consider both patient and caregiver preferences for formulation and
dosing frequency to ensure the treatment aligns with the patient’s goals.1 Additionally, pharmacokinetic
simulations can be used to evaluate various dosing and patient scenarios encountered in clinical practice,
enabling clinicians to tailor dosing recommendations for optimal patient outcomes.[3]
References:
[1] Pungor et al. BMC Psychiatry 2021;21(1):300.
[2] Lencer et al. Compr Psychiatry 2021;107:152233.
[3] Wang et al. Clin Pharmacol Drug Dev 2024;13(6):631643.
ISS03 Towards full recovery of major depressive disorder/treatment-resistant depression: from
treatment optimisation to patient perspectives
13:20 - 14:40
Industry Satellite Symposium
Industry session financially supported by Janssen Pharmaceutica NV, a Johnson & Johnson Company
The first presentation in this Satellite Symposium aims to provide an understanding the burden of major
depressive disorder/treatment-resistant depression using patient-reported outcomes. The second
presentation will focus on using a personalised approach for the management of major depressive
disorder/treatment-resistant depression, with the third presentation focusing on using real-world
evidence to inform on the management of major depressive disorder/treatment-resistant depression.
Patient case(s) may be included to support the presentations all symposium presenters will have the
opportunity to discuss the case(s) and provide their perspective. The symposium with conclude with an
audience Q&A session.
Educational financial support is provided by Johnson & Johnson.